Abbott Laboratories (ABT) News

Abbott Laboratories (ABT): $100.68

-0.39 (-0.39%)

POWR Rating

Component Grades













Filter ABT News Items

ABT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABT News Highlights

  • For ABT, its 30 day story count is now at 22.
  • Over the past 14 days, the trend for ABT's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • The most mentioned tickers in articles about ABT are CODX, LI and LINK.

Latest ABT News From Around the Web

Below are the latest news stories about ABBOTT LABORATORIES that investors may wish to consider to help them evaluate ABT as an investment opportunity.

DexCom: Great Products, Stock Is Too Expensive


DexCom (DXCM) has risen sharply in recent years until the beginning of this year. The stock has entered a bear market. This is probably mainly due to the Fed's strict policy to contain inflation. Interest rates are rising sharply, correcting the prices of expensive growth stocks. DexCom is also a growth stock whose share price has declined.

Data by Yannick Frey on Seeking Alpha | September 21, 2022

10 Best Defensive Stocks to Buy According to Ray Dalio

In this article, we will look at the 10 best defensive stocks to buy according to Ray Dalio. If you want to explore similar stocks, you can also take a look at 5 Best Defensive Stocks to Buy According to Ray Dalio. Ray Dalio is a billionaire investor and hedge fund manager of Bridgewater Associates, […]

Yahoo | September 21, 2022

Quant Billionaire Jim Simons Loves These 10 Defensive Stocks

In this article, we discuss 10 defensive stocks that quant billionaire Jim Simons loves. If you want to read about some more stocks in the Simons portfolio, go directly to Quant Billionaire Jim Simons Loves These 5 Defensive Stocks. James Simons, the founder of New York-based Renaissance Technologies, manages an equity portfolio worth more than […]

Yahoo | September 21, 2022

FDA Concludes Oversight Shortcomings After Infant Formula Internal Review

The FDA concluded an internal review of agency actions related to the U.S. infant formula supply. The agency released a 10-page report, which is the result of information collected from more than 40 interviews with more than 60 FDA staff and leadership directly involved with the events that transpired. The review found that numerous shortcomings hampered the agency’s response to the U.S. infant formula supply problems this year. The FDA said a “confluence of systemic vulnerabilities” helped expl

Yahoo | September 21, 2022

Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Yahoo | September 21, 2022

FDA Baby Formula Oversight Is Criticized in Internal Review

Numerous shortcomings including outdated technology hampered response to this year’s nationwide shortage.

Yahoo | September 21, 2022

Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Tops Revenue Estimates

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 33.33% and 0.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | September 20, 2022

Abbott (ABT) Gains But Lags Market: What You Should Know

In the latest trading session, Abbott (ABT) closed at $104.09, marking a +0.09% move from the previous day.

Yahoo | September 19, 2022

Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies

Abbott (NYSE: ABT) today announced data from five late-breaking presentations showing the benefits of its minimally invasive devices in treating people with a range of structural heart diseases. Data include findings that reinforce the value of MitraClip™, the world's first and leading transcatheter edge-to-edge repair (TEER) device, to treat leaky valves in people with mitral regurgitation (MR).

Yahoo | September 17, 2022

Abbott Faces Competition From Heart Valve Device Cleared by FDA

A system from Edwards Lifesciences that has been cleared by the Food and Drug Administration gives patients an alternative after years of a single company dominating the market.

Yahoo | September 17, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.532 seconds.